Back to News
Market Impact: 0.05
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Source: PR Newswire
Healthcare & Biotech
The provided excerpt identifies Innovent Biologics as a biopharmaceutical company but contains no specific announcement, financial results, or other event to assess.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- ArriVent reports phase 1 data for cancer drug ARR-217
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- UK immigration crackdown threatens £15 billion care sector
- US Midterm Elections 2026: Key Issues, From Affordability to AI
- Billy Evans’ ‘Theranos 2.0’ startup has patents, investors, and a missing CTO—but no product